Evaluation of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule EpCAM (GA733-2), and carbohydrate antigen 19-9 (CA 19-9) levels in colorectal cancer patients and correlation with clinicopathological characteristics

Clinical Laboratory

Volumn 58, Issue 5-6, 2012, Pages 441-448

  Mourtzikou, Antonia ^a   Stamouli, Marilena ^b   Kroupis, Christos ^a   Christodoulou, Spyridon ^a   Skondra, Marika ^a   Kastania, Anastasia ^c   Pectasides, Demetrios ^a   Athanasas, Georgios ^a   Dimas, Claire ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b Naval and Veterans Hospital   (Greece)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

CA 19 9; CEA; Colorectal cancer; EGFR; EpCAM (GA733 2)

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE;

AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL EVALUATION; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; ELECTROCHEMICAL ANALYSIS; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; ANTIGENS, NEOPLASM; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULES; COLORECTAL NEOPLASMS; ELECTROCHEMICAL TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84863691932     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Parkin DM, Bray F, Pisani P. Global cancer statistics. CA Cancer J Clin 2006;55:74-108.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. (Pubitemid 351521864)
3. Curado M, Edwards B, Shin H, et al. Cancer incidence in five continents. Vol. IX. IARC Scientific Publications No. 160, Lyon 2007.
4. Boyle P, Leon ME. Epidemiology of colorectal cancer. Br Med Bull 2002;64:1-25. (Pubitemid 35238576)
5. Haggar FA, BousheyRP. Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors. Clinics in colon and rectal surgery 2009;22(4):191-7.
6. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006;101:385-98. (Pubitemid 43381685)
7. Joint WHO/FAO Expert Report on Diet, Nutrition, and the Prevention of Chronic Disease. Geneva, Switzerland: World Health Organization, 2003.
8. Santarelli RL, Pierre F, Corpet DE. Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. Nutr Cancer 2008;60(2):131-44. (Pubitemid 351454023)
9. Newmark HL, Yang K, Lipkin M, et al. A Western-style diet induces benign and malignant neoplasms in the colon of normal C57B1/6 mice. Carcinogenesis 2001;22:1871-5. (Pubitemid 33064854)
10. Johnson IT, Lund EK. Nutrition, obesity and colorectal cancer. Aliment Pharmacol Ther 2007;26:161-81.
11. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum Tumor Markers. Am Fam Physician 2003;68(6):1076-82.
12. Spano JP, Lagorce C, Atlan D, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Annals of Oncology 2005;16:102-8. (Pubitemid 40124486)
13. www.cancer.gov/cancertopics/factsheet/detection/staging
14. Kievit J. Follow-up of patients with colorectal cancer: numbers need to test and treat. Eur J Cancer 2002;38:986-99. (Pubitemid 34442327)
15. Brünner N, Haglund C, Holten-Andersen M, Nielsen HJ, Duffy MJ. National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Colorectal Cancer. Available at www.aacc.org/SiteCollectionDocuments/ NACB/LMPG/tumor/chp3c-colorectal.pdf
16. Went P, Dirnhofer S, Schöpf D, Moch H, Spizzo G. Expression and Prognostic significance of EpCAM. J Cancer Mol 2008;3(6):164-74.
17. Mc Donald JH. Handbook of Biological Statistics. Sparky House Publishing, Baltimore, Maryland 2009 (2nd ed.).
18. Duffy MJ, van Dalen A, Haglund C, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. European Journal of Cancer 2007;43:1348-60. (Pubitemid 46874070)
19. Müller M, Vogl M. Tumor markers: Rational Use. Available at http://www.ifcc.org/ejifcc/vo116no2/160206200507.htm
20. Belluco C, Nitti D, Frantz M, et al. Interleukin-6 Blood Level Is Associated With Circulating Carcinoembryonic Antigen and Prognosis in Patients With Colorectal Cancer. Annals of Surgical Oncology 2000;7(2):133-8. (Pubitemid 30164682)
21. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R. Multi variate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 2000;20(6D):5195-8. (Pubitemid 32319106)
22. Basbug M, Arikanoglu Z, Bulbuller N, et al. Prognostic value of preoperative CEA and CA 19-9 levels in patients with colorectal cancer. Hepato-Gastroenterology 2011;58(106):400-5.
23. Went PTH, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Human Pathology 2004;35(1):122-8. (Pubitemid 38133932)
24. Spizzo G, Went P, Dirnhofer S, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004,86:207-213. (Pubitemid 39070963)
25. Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J, van Krieken JH. Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 2005,92:1767-72. (Pubitemid 40756490)
26. Zaloudik J, Basak S, Nesbit M, et al. Expression of an antigen homologous to the human CO17-1A/GA733 colon cancer antigen in animal tissues. Br J Cancer 1997;76:909-16. (Pubitemid 27401943)
27. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G. Ep-CAM over-expression in breast cancer as a predictor of survival. Lancet 2000;356:1981-2.
28. Joo M, Kim H, Kim MK, Yu HJ, Kim JP. Expression of Ep-CAM in intestinal metaplasia, gastric epithelial dysplasia and gastric adenocarcinoma. J Gastroenterol Hepatol 2005;20:1039-45. (Pubitemid 40961226)
29. Xin Xie, Chun-Yan Wang, Yun-Xin Cao, et al. Expression pattern of epithelial cell adhesion molecule on normal and malignant colon tissues. World J Gastroenterol 2005;11(3):344-7.
30. Bernardina TF, van der Gun, Lieuwe J, et al. EpcamEpCAM in carcinogenesis: the Good, the Bad or the Ugly. Carcinogenesis 2010;31(11):1913-21.
31. Cheirsilpa A, Ruangvejvorachai P, Karalak A, Sangprakarn S, Pummai S, Sangrajrang S. Determination of epidermal growth factor receptor (EGFR) in patients with colorectal cancer. Cancer Therapy 2007;5:137-42.
32. Arteaga CL. The Epidermal Growth Factor Receptor: From Mutant Oncogene in Non-human Cancers to Therapeutic Target in Human Neoplasia. Journal of Clinical Oncology 2001;19(18s):32s-40s. (Pubitemid 32880077)
33. Yarden Y. The EGFR family and its ligands in human cancer signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(Suppl 4):S3-S8. (Pubitemid 32938123)
34. Goldstein NS, Armin M. Epidermal Growth Factor Receptor Immunohistochemical Reactivity in Patients with Cancer Stage IV Colon Adenocarcinoma. Cancer 2001;92(5):1331-45.
35. Shankaran V, Obel J, Benson AB. Predicting Response to EGFR Inhibitors in Metastatic Colorectal Cancer: Current Practice and Future Directions. The Oncologist 2010;15:157-67.
36. Gui Fang Guo, Yu Chen Cai, Bei Zhang, Rui Hua Xu, Hui Juan Qiu, Liang Ping Xia, Wen Qi Jiang, Pei Li Hu,Xu Xian Chen and Fei Fei Zhou, et al. Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Medical Oncology 2011;28(S1):197-203.
37. McKay JA, Murray LJ, Curran S, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumors and lymph node metastases. Eur J Cancer 2002;38:2258-64. (Pubitemid 35346467)
38. Mohhamadi G, Jamialahmadi K, Lary S, Ghaffarzadegan K. Expression of membranous epidermal growth factor receptor in colorectal adenocarcinoma and its correlation with clinicopathological features. Pakistan Journal of Biological Sciences 2011;14(5):357-62.
39. Abd EAHS, Mishriky AM, Mohamed FA. Epidermal growth factor receptor in colorectal carcinoma: correlation with clinicopathological prognostic factors. Colorectal Dis 2008;10:170-8.
40. Kimura H, Kato H, Faried A, et al. Prognostic significance of EpCAM expression in human esophageal cancer. International Journal of Oncology 2007; 30(1):171-9.
41. Grotowski M, Maruszyński M, Piechota W. Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients. Pol Merkur Lekarski. 2001 Dec;11(66):476-9.
42. Tanaka T, Tanaka M, Tanaka T, Ishigamori R. Biomarkers for Colorectal Cancer. Int J Mol Sci 2010;11:3209-25.